Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies
Michael J. Peluso, Khamal Anglin, Matthew S. Durstenfeld, et al.
Pathogens and Immunity (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
Yuyong Zhou, Karen Anbro Gammeltoft, Line A. Ryberg, et al.
Science Advances (2022) Vol. 8, Iss. 51
Open Access | Times Cited: 165
Chronic viral coinfections differentially affect the likelihood of developing long COVID
Michael J. Peluso, Tyler‐Marie Deveau, Sadie E. Munter, et al.
Journal of Clinical Investigation (2022) Vol. 133, Iss. 3
Open Access | Times Cited: 146
Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics
Albert Leng, Manuj M. Shah, Syed A. Ahmad, et al.
Cells (2023) Vol. 12, Iss. 5, pp. 816-816
Open Access | Times Cited: 113
Long COVID: An inevitable sequela of SARS-CoV-2 infection
Chih‐Cheng Lai, Chi‐Kuei Hsu, Muh‐Yong Yen, et al.
Journal of Microbiology Immunology and Infection (2022) Vol. 56, Iss. 1, pp. 1-9
Open Access | Times Cited: 98
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Seyed Mohammad Reza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114367-114367
Open Access | Times Cited: 90
Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative
Hector Bonilla, Michael J. Peluso, Kathleen E. Rodgers, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 58
Thromboinflammation in long COVID—the elusive key to postinfection sequelae?
Leo Nicolai, Rainer Kaiser, Konstantin Stark
Journal of Thrombosis and Haemostasis (2023) Vol. 21, Iss. 8, pp. 2020-2031
Open Access | Times Cited: 51
Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2
Kailin Yin, Michael J. Peluso, Xiaoyu Luo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 47
Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort study
Matthew S. Durstenfeld, Michael J. Peluso, Feng Lin, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 1
Open Access | Times Cited: 27
Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
Alison K. Cohen, Toni Wall Jaudon, Eric M. Schurman, et al.
Communications Medicine (2025) Vol. 4, Iss. 1
Open Access | Times Cited: 2
The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls
Jay Pandit, Jennifer M. Radin, Danielle Chiang, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 1, pp. 25-31
Open Access | Times Cited: 37
Tissue‐resident memory T cells and lung immunopathology
In Su Cheon, Young Min Son, Jie Sun
Immunological Reviews (2023) Vol. 316, Iss. 1, pp. 63-83
Open Access | Times Cited: 33
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106708-106708
Open Access | Times Cited: 31
Viral persistence in children infected with SARS-CoV-2: current evidence and future research strategies
Danilo Buonsenso, Laura Martino, Rosa Morello, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 9, pp. e745-e756
Open Access | Times Cited: 30
Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness
Pratik P. Pandharipande, Shawniqua Williams Roberson, Fiona E. Harrison, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 8, pp. 726-738
Open Access | Times Cited: 30
Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review
César Fernández‐de‐las‐Peñas, Juan Torres‐Macho, Jesus Alfonso Catahay, et al.
Infection (2023) Vol. 52, Iss. 1, pp. 43-58
Closed Access | Times Cited: 23
Impact of Pre-Existing Chronic Viral Infection and Reactivation on the Development of Long COVID
Michael J. Peluso, Tyler‐Marie Deveau, Sadie E. Munter, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 31
Long COVID: what is known and what gaps need to be addressed
Benjamin A. Krishna, Mark R. Wills, Nyaradzai Sithole
British Medical Bulletin (2023) Vol. 147, Iss. 1, pp. 6-19
Open Access | Times Cited: 17
Substantial health and economic burden of COVID-19 during the year after acute illness among US adults not at high risk of severe COVID-19
Amie Scott, Wajeeha Ansari, Richard Chambers, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Long COVID and its association with neurodegenerative diseases: pathogenesis, neuroimaging, and treatment
Jinyang Zhao, Fan Xia, Xue Jiao, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 5
Long Covid in Older Adults: Functional Outcomes and Treatment Effectiveness
Brittin Wagner, Kate Mathers, Aaron Norfolk, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Ocular neuroinflammatory response secondary to SARS-CoV-2 infection-a review
Yun Zhao, Ying Tang, Qi Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Long COVID and rheumatology: Clinical, diagnostic, and therapeutic implications
Cassandra Calabrese, E. Kirchner, Leonard H. Calabrese
Best Practice & Research Clinical Rheumatology (2022) Vol. 36, Iss. 4, pp. 101794-101794
Open Access | Times Cited: 22
Paxlovid as a potential treatment for long COVID
Matthew W. McCarthy
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 17, pp. 1839-1843
Closed Access | Times Cited: 12
Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
Karen Anbro Gammeltoft, Yuyong Zhou, Line A. Ryberg, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1970-1970
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top